Chitosan microspheres as potential vaccine delivery systems

International Journal of Drug Delivery

Volumn 3, Issue 1, 2011, Pages 43-50

  Saravana Kumar, A ^a   Ramaswamy, N M ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

Biodegradable polymers; Chitosan microspheres; Tetanus toxoid; Vaccine delivery system

Indexed keywords

ALUMINUM SALT; CHITIN; CHITOSAN; DIPHTHERIA TOXIN; DIPHTHERIA VACCINE; MICROSPHERE; PERTUSSIS TOXIN; POLYGLACTIN; POLYLACTIDE; TETANUS TOXOID; VACCINE; ANTIGEN; IMMUNOLOGICAL ADJUVANT; POLYMER;

CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; IMMUNOGENICITY; IMMUNOREACTIVITY; MICROENCAPSULATION; MUCOADHESION; NONHUMAN; REVIEW; SUSTAINED DRUG RELEASE; VACCINATION; BIOCOMPATIBILITY; BIODEGRADATION; CONTROLLED RELEASE FORMULATION; ENCAPSULATION;

EID: 84898698883     PISSN: None     EISSN: 09750215     Source Type: Journal    
DOI: 10.5138/ijdd.2010.0975.0215.03052     Document Type: Review

References (46)

1. Plotkin SL, Plotkin SA, in: Plotkin SA, Mortimer EA Jr. (Eds). A short history of vaccination and vaccines, Saunders, Philadelphia, PA, 1988, 1-7.
2. Shari Lofthouse. Immunological aspects of controlled antigen delivery. Adv Drug Deli Rev 2002; 54:863-870.
3. Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. A Single administration of tetanus toxin in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminium hydroxide. Vaccine 1995; 13:683-689.
4. Warren HS, Vogel FR, Chedid LA. Current status of immunological adjuvants. Ann Rev Immunol 1986;4: 369-376.
5. Kohn J, Niemi SM, Albert EC, Murphy JC, Langer RS, Fox JG. Single-step immunization using a controlled release, biodegradable polymer with sustained adjuvant activity. J Immunol Methods 1986; 95: 31-37.
6. Physician's Desk Reference, 46th ed, Medical Economics Data. 1992; 1544-1546.
7. Bittle JL, Murphy FL. Vaccine Biotechnol. 1989; 33: 313.
8. Allison AC, Byars NE. Immunological adjuvants: desirable properties and side effects. Molec Immunol 1991; 28: 279-283.
9. Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 1996; 85 (12): 1261-1270.
10. Nellore RV, Pande PG, Young D, Bhagat HR. Evaluation of biodegradable microspheres as vaccine adjuvant for Hepatitis B surface antigen. J Parenteral Sci Tech 1992; 46: 176-180.
11. Yamaguchi K, Anderson JM. In vivo biocompatibility studies of medisorb 65/35 D. L-lactide/glycolide copolymer microspheres. J Control Release 1993; 24: 81-86.
12. Aguado MT, Lambert PH. Controlled release vaccines biodegradable polylactide-polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiol 1992;184: 113-125.
13. Esparza I, Kissel T. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine 1992; 10: 714-720.
14. Raghuvanshi RS, Singh M, Talwar GP. Biodegradable delivery system for single step immunization with tetanus toxoid. Int J Pharm 1993; 93: R1-R5.
15. Alonso MJ, Cohen S, Park TG, Gupta RK, Siber GR, Langer R. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm. Res 1993;10: 945-953.
16. Alonso MJ, Gupta RK, Min C, Siber GR, Langer R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994; 12: 299-306.
17. Change AC, Gupta RK. Stabilization of tetanus toxoid in poly (D, L, lactide-co-glycolic acid) microspheres for the controlled release of antigen. J Pharm Sci 1996; 85: 129-132.
18. Langer R. New methods of drug delivery. Science 1990; 249: 1527-1533.
19. Tice TR, Mason DW, Ghley RM. Clinical use and future of parenteral microspheres delivery systems, in: F. Prescot, W.S. Nimmo (Eds.), Drug Delivery and its Therapeutic Applications, Wiley, London, 1989, Chapter 21.
20. Wise DL, Fellman TD, Sanderson JE, Wentworth RL. Lactide/glycolide polymers used in as surgical suture material, raw material for osteosynthesis and in sustained release forms of drugs, in:G. Gregoriadis (Ed.), Drug Carriers in Medicine, Academic Press, London. 1979; 237.
21. Singh M, Li XM, Wang HY, McGee JP, Zamb T, Koff W, Wang CY, O'Hagan DT. Immunogenecity and protection in small animal models with controlled release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997;65: 1716-1721.
22. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15:1326-1331.
23. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 1998; 24:979-993.
24. Joane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999; 178:55-65.
25. Vander Lubben LM, Verhoef JC, Borchard G, Junginger HE. Chitosans for mucosal vaccination. Adv Drug Deliv Rev 2001;52:139-144.
26. Derek T, O'Hagan DT, Rino Rappuoli. Novel approaches to vaccine delivery. Pharmaceutical Research 2004; 21(9): 1519-1530.
27. Valiante NM, O'Hagan DT, Ulmer J. Innate immunity and biodefense vaccines. Cell Microbiol 2003; 5:755-760.
28. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11:1358-1361.
29. Borchard G, Luessen HL, De Boer AG, Verhoef JC, Lehr CM, Junginger HE. The poteltial of mucoadhesive polymers in enhancing intestinal peptide drus absorption. III: Effect of chitosan glutamate and carbomer on epithelial tight junctions in vitro. J Control Release 1996; 39:131-138.
30. Dodane V, Khan MA, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999; 182:21-32.
31. Schipper NG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res 1996; 13:1686-1692.
32. Luessen HL, de Leeuw BJ, Langemeyer MW, de Boer AB, Verhoef JC, Junginger HE. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 1996; 13:1668-1672.
33. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998; 16:2039-2046.
34. McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM (197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2000; 19:1188-1198.
35. Xie Y, Zhou NJ, Gong YF, Zhou XJ, Chen J, Hu SJ, et al. Th immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 2007; 13:1547-1553.
36. Seferian PG, Martinez ML. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000; 19:661-668.
37. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217:183-191.
38. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14:1568-1573.
39. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991; 59:2978-2986.
40. O'Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993a; 11:965-969.
41. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 1998;29:185-194.
42. Chowdary KP, Rao YS. Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull 2004;27:1717-1724.
43. Tian J, Yu J, Sun X. Chitosan microspheres as candidate plasmid vaccine carrier for oral immunisation of Japanese flounder (Paralichthys olivaceus). Vet Immunol Immunopathol 2008; 126:220-229.
44. Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 2007;33:1112-1124.
45. Takahiro Nagamoto, Yoshiyuki Hattori, Kozo Takayama, Yoshie Maitani. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharmacological Research, 21(4), 671-674 (2004).
46. Arthanari Saravanakumar, Nachipalayam Muthusamy Ramaswamy. Formulation and in-vitro evaluation of tetanus toxoid loaded chitosan microspheres. J of Pharm Research 2009; 2(5): 893-896.